Safety and efficacy of tibolone and menopausal transition: a randomized, double-blind placebo-controlled trial

References

• Nejat EJ, Chervenak JL. The continuum of ovarian aging and clinicopathologies associated with the menopausal transition. Maturitas 2010;66:187–190.
   PubMed Web of Science ®Google Scholar
• Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S, Nelson DB. Defining menopause status: Creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005;12:128–135.
   PubMed Web of Science ®Google Scholar
• Santoro N, Chervenak JL. The menopause transition. Endocrinol Metab Clin North Am 2004;33:627–636.
   PubMed Web of Science ®Google Scholar
• Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med 2001;10:843–848.
   PubMedGoogle Scholar
• Maclennan AH. Evidence-based review of therapies at the menopause. Int J Evid Based Healthc 2009;7:112–123.
   PubMedGoogle Scholar
• The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242–255.
   PubMed Web of Science ®Google Scholar
• Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21–28.
   PubMed Web of Science ®Google Scholar
• Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric 2010;13:317–327.
   PubMed Web of Science ®Google Scholar
• Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87:16–23.
   PubMed Web of Science ®Google Scholar
• Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: A review based on recent randomised controlled clinical trials. Gynecol Endocrinol 2010;26:804–814.
   PubMed Web of Science ®Google Scholar
• El-Hajj Fuleihan G. Tibolone and the promise of ideal hormone-replacement therapy. N Engl J Med 2008;359:753–755.
   PubMed Web of Science ®Google Scholar
• Albertazzi P, Di Micco R, Zanardi E. Tibolone: A review. Maturitas 1998;30:295–305.
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tissue-selectivity: The mechanism of action of tibolone. Maturitas 2004;48(Suppl 1):30–40.
   PubMedGoogle Scholar
• Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: A multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13:917–925.
   PubMed Web of Science ®Google Scholar
• Obenauer S, Hermann KP, Grabbe E. Applications and literature review of the BI-RADS classification. Eur Radiol 2005;15:1027–1036.
   PubMed Web of Science ®Google Scholar
• Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17β-estradiol on climacteric symptoms in women with surgical menopause: A randomized, cross-over study. Maturitas 2007;56:61–68.
   PubMed Web of Science ®Google Scholar
• Azevedo GD, Prado MFM, Ferriani RA, Reis RM, Berezowski AT, Maranhão TMO, et al. Raloxifene therapy does not affect uterine blood flow in postmenopausal: A transvaginal Doppler study. Maturitas 2004;47:195–200.
   PubMed Web of Science ®Google Scholar
• Azevedo GD, Silveira IL, Petronillo PA, Souza MO, Costa e Silva TDN et al. Prevalência de Sintomas do Climatério em mulheres dos meios rural e urbano do Rio Grande do Norte, Brasil. Rev Bras Ginecol Obstet 2007;29:420–427.
   Google Scholar
• Freitas AK, Freitas RA Jr, Prado MF, Azevedo GD, Foss MC, Silva-de-Sá MF, Ferriani RA. [Tibolone treatment of diabetic postmenopausal women: Clinical and laboratory safety parameters]. Arq Bras Endocrinol Metabol 2005;49:433–440.
   PubMedGoogle Scholar
• Nijland EA, Nathorst-Böös J, Palacios S, van de Weijer PW, Davis S, Stathopoulos VM, Birkhaeuser MH, et al.; LISA study investigators group. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114–121.
   PubMed Web of Science ®Google Scholar
• Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Impact on uterine bleeding and endometrial thickness: Tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299–306.
   PubMed Web of Science ®Google Scholar
• Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006;53:413–423.
   PubMed Web of Science ®Google Scholar
• Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25–31.
   PubMed Web of Science ®Google Scholar
• Alder E. The Blatt-Kupperman menopausal index: A critique. Maturitas 1998;29:19–24.
   PubMed Web of Science ®Google Scholar
• Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109:1109–1114.
   PubMed Web of Science ®Google Scholar
• Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T. Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J Steroid Biochem Mol Biol 2009;116:8–14.
   PubMed Web of Science ®Google Scholar
• Lam PM, Cheung GW, Shek DT, Lee DT, Haines CJ, Chung TK. A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses. Menopause 2004;11:416–422.
   PubMed Web of Science ®Google Scholar
• Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE; OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746–755.
   PubMed Web of Science ®Google Scholar
• Stuckey BG, Barrett PH, Wagner JM, Hampton RA, Chan DC, Brown SJ, Watts GF. The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy. Clin Endocrinol (Oxf) 2010;73:497–501.
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women. Maturitas 1990;12:37–42.
   PubMed Web of Science ®Google Scholar
• Crona N, Silfverstolpe G, Samsioe G. A double-blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol 1983;102:451–455.
   PubMedGoogle Scholar
• Wiegratz I, Starflinger F, Tetzloff W, Leifels-Fischer B, Helmond FA, Dericks-Tan JS, Kuhl H. Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas 2002;41:133–141.
   PubMed Web of Science ®Google Scholar
• Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, Helmond F. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002;109:886–893.
   PubMed Web of Science ®Google Scholar
• Meuwissen JH, Wiegerinck MA, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995;21:121–125.
   PubMed Web of Science ®Google Scholar